Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer

Biomed Pharmacother. 2023 Dec 31:169:115866. doi: 10.1016/j.biopha.2023.115866. Epub 2023 Nov 10.

Abstract

Triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, presents severe threats to women's health. Therefore, it is critical to find novel treatment approaches. Ferroptosis, a newly identified form of programmed cell death, is marked by the buildup of lipid reactive oxygen species (ROS) and high iron concentrations. According to previous studies, ferroptosis sensitivity can be controlled by a number of metabolic events in cells, such as amino acid metabolism, iron metabolism, and lipid metabolism. Given that TNBC tumors are rich in iron and lipids, inducing ferroptosis in these tumors is a potential approach for TNBC treatment. Notably, the metabolic adaptability of cancer cells allows them to coordinate an attack on one or more metabolic pathways to initiate ferroptosis, offering a novel perspective to improve the high drug resistance and clinical therapy of TNBC. However, a clear picture of ferroptosis in TNBC still needs to be completely revealed. In this review, we provide an overview of recent advancements regarding the connection between ferroptosis and amino acid, iron, and lipid metabolism in TNBC. We also discuss the probable significance of ferroptosis as an innovative target for chemotherapy, radiotherapy, immunotherapy, nanotherapy and natural product therapy in TNBC, highlighting its therapeutic potential and application prospects.

Keywords: Ferroptosis; Metabolic reprogramming; Therapy; Triple-negative breast cancer (TNBC).

Publication types

  • Review

MeSH terms

  • Amino Acids
  • Cell Line, Tumor
  • Female
  • Ferroptosis*
  • Humans
  • Iron
  • Lipid Metabolism
  • Triple Negative Breast Neoplasms* / drug therapy

Substances

  • Amino Acids
  • Iron